Annabel Nixon

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Replacement Therapy

Neuropathic Pain

Top Venues

Calcified tissue international

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Kamenickỷ, Karine Briot, Maria Luisa Brandi, Martine Cohen Solal, Rachel Katherine Crowley, Richard Keen, Sami Kolta, Robin H Lachmann, Anne-Lise Lecoq, Stuart H Ralston, Jennifer S Walsh, Angela J Rylands, Angela Williams, Wei Sun, Annabel Nixon, Mark Nixon, Muhammad Kassim Javaid
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD open 9 (1) (2023)
Peter Kamenickỷ, Karine Briot, Maria Luisa Brandi, Martine Cohen Solal, Rachel Katherine Crowley, Richard Keen, Sami Kolta, Robin H Lachmann, Anne-Lise Lecoq, Stuart H Ralston, Jennifer S Walsh, Angela J Rylands, Angela Williams, Wei Sun, Annabel Nixon, Mark Nixon, Muhammad Kassim Javaid
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD open 9 (1) (2023)
Suzanne M Jan de Beur, Tricia Cimms, Annabel Nixon, Christina Theodore-Oklota, Diana Luca, Mary Scott Roberts, Shayna Egan, Christina A Graham, Elizabeth Hribal, Christopher J Evans, Sue Wood, Angela Williams
Burosumab improves patient-reported outcomes in adults with tumor-induced osteomalacia: mixed-methods analysis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2023)
Peter Kamenickỷ, Karine Briot, Maria Luisa Brandi, Martine Cohen Solal, Rachel Katherine Crowley, Richard Keen, Sami Kolta, Robin H Lachmann, Anne-Lise Lecoq, Stuart H Ralston, Jennifer S Walsh, Angela J Rylands, Angela Williams, Wei Sun, Annabel Nixon, Mark Nixon, Muhammad Kassim Javaid
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD open 9 (1) (2023)
Peter Kamenickỷ, Karine Briot, Maria Luisa Brandi, Martine Cohen Solal, Rachel Katherine Crowley, Richard Keen, Sami Kolta, Robin H Lachmann, Anne-Lise Lecoq, Stuart H Ralston, Jennifer S Walsh, Angela J Rylands, Angela Williams, Wei Sun, Annabel Nixon, Mark Nixon, Muhammad Kassim Javaid
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD open 9 (1) (2023)
Peter Kamenickỷ, Karine Briot, Maria Luisa Brandi, Martine Cohen Solal, Rachel Katherine Crowley, Richard Keen, Sami Kolta, Robin H Lachmann, Anne-Lise Lecoq, Stuart H Ralston, Jennifer S Walsh, Angela J Rylands, Angela Williams, Wei Sun, Annabel Nixon, Mark Nixon, Muhammad Kassim Javaid
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD open 9 (1) (2023)
Maria Luisa Brandi, Suzanne M Jan de Beur, Karine Briot, Thomas O Carpenter, Hae Il Cheong, Martine Cohen Solal, Rachel Katherine Crowley, Richard Eastell, Yasuo Imanishi, Erik Allen Imel, Steven W Ing, Karl L Insogna, Nobuaki Ito, Muhammad Kassim Javaid, Peter Kamenickỷ, Richard Keen, Takuo Kubota, Robin H Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Anthony A Portale, Stuart H Ralston, Hiroyuki Tanaka, Thomas J Weber, Han Wook Yoo, Wei Sun, Angela Williams, Annabel Nixon, Yasuhiro Takeuchi
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcified tissue international 111 (4) (2022)
Raja Padidela, Michael P Whyte, Francis H Glorieux, Craig Frank Munns, Leanne M Ward, Ola Nilsson, Anthony A Portale, Jill H Simmons, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angela Williams, Annabel Nixon, Wei Sun, Angel Chen, Alison Skrinar, Erik Allen Imel
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified tissue international 108 (5) (2021)
Annabel Nixon, Elina Roddick, Karen Moore, Diane Wild
A qualitative investigation into the impact of hemophagocytic lymphohistiocytosis on children and their caregivers. Orphanet journal of rare diseases 16 (1) (2021)